bexagliflozin (Brenzavvy)

Indications

• treatment of adults with diabetes mellitus type 2

Dosage

• 20 mg PO QD

Dosage adjustment in renal failure

• approved for use in adults with eGFR > 30 mL/min/1.73m2

Adverse effects

• ketoacidosis
• lower limb amputation
• volume depletion
• urosepsis
• pyelonephritis
• Fournier's gangrene
• genital mycotic infections
• hypoglycemia

• drug adverse effects of hypoglycemic agents
• drug adverse effects of oral glucosuric agent; SGLT-2 inhibitor; flozin

Drug interactions

• hypoglycemia when used in combination with insulin or drugs that enhance insulin secretion (sulfonylurea)

• drug interaction(s) SGLT2 inhibitors (flozins) with diuretics
• drug interaction(s) of SGLT-2 inhititor (flozin) in combination with GLP1-agonist
• drug interaction(s) of aldosterone antagonists with SGLT2-inhibitor
• drug interaction(s) of fluoroquinolones with hypoglycemic agents

Mechanism of action

• reduction of blood glucose by increasing glucosuria
• all flozins inhibit sodium-glucose cotransporter 2 (SGLT2) thus inhibiting reuptake of glucose by the renal tubules

More general terms

• SGLT-2 inhibitor; oral glucosuric agent; flozin